Want to see JP:190A full AI Analyst Report?
190A Stock Chart & Stats
¥108.00
-¥9.00(-2.81%)
At close: 4:00 PM EST
¥108.00
-¥9.00(-2.81%)
Day’s Range― - ―
52-Week Range¥66.00 - ¥184.00
Previous CloseN/A
Volume2.20M
Average Volume (3M)565.44K
Market Cap
¥5.72B
Enterprise Value¥5.70K
Total Cash (Recent Filing)¥2.51B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Oct 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.05
Shares Outstanding77,258,400
10 Day Avg. Volume542,310
30 Day Avg. Volume565,443
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-6.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetNo reported debt limits interest and refinancing risk, giving Chordia greater flexibility to fund clinical development. This is particularly valuable for an R&D-stage biotech whose future financing needs may remain significant before commercialization.
Orphan-drug Regulatory SupportDual orphan designations validate rogocekib’s relevance in a high-unmet-need indication and may provide development subsidies, regulatory interaction and potential incentives. These benefits can improve the program’s strategic position as clinical development progresses.
Research Collaboration And Pipeline DepthGovernment-backed collaboration with Kyoto University adds external research support and scientific credibility while reducing some development burden. Multiple targeted oncology programs also diversify pipeline potential beyond the lead asset and support longer-term innovation capacity.
Bears Say
Persistent Pre-revenue LossesThe absence of revenue leaves Chordia dependent on financing and successful clinical progress rather than recurring operating income. Continued large losses reduce financial visibility and make the company’s ability to reach commercialization dependent on future development outcomes.
Heavy Cash BurnSustained operating and free-cash-flow outflows show that research spending is not currently funded by the business. Continued burn can shorten the funding runway and increase reliance on equity issuance or partnerships before products generate cash.
Shrinking Capital Base And DilutionFalling equity reflects cumulative losses and reduces the capital cushion available for development. The increase in shares outstanding indicates equity financing, creating dilution risk for existing holders while the company remains pre-revenue and cash-consuming.
Chordia Therapeutics Inc. News
190A FAQ
What was Chordia Therapeutics Inc.’s price range in the past 12 months?
Chordia Therapeutics Inc. lowest stock price was ¥66.00 and its highest was ¥184.00 in the past 12 months.
What is Chordia Therapeutics Inc.’s market cap?
Chordia Therapeutics Inc.’s market cap is ¥5.72B.
When is Chordia Therapeutics Inc.’s upcoming earnings report date?
Chordia Therapeutics Inc.’s upcoming earnings report date is Oct 09, 2026 which is in 42 days.
How were Chordia Therapeutics Inc.’s earnings last quarter?
Chordia Therapeutics Inc. released its earnings results on Jul 15, 2026. The company reported -¥14.45 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Chordia Therapeutics Inc. overvalued?
According to Wall Street analysts Chordia Therapeutics Inc.’s price is currently Overvalued.
Does Chordia Therapeutics Inc. pay dividends?
Chordia Therapeutics Inc. does not currently pay dividends.
What is Chordia Therapeutics Inc.’s EPS estimate?
Chordia Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chordia Therapeutics Inc. have?
Chordia Therapeutics Inc. has 77,258,400 shares outstanding.
What happened to Chordia Therapeutics Inc.’s price movement after its last earnings report?
Chordia Therapeutics Inc. reported an EPS of -¥14.45 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.173%.
Which hedge fund is a major shareholder of Chordia Therapeutics Inc.?
Currently, no hedge funds are holding shares in JP:190A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chordia Therapeutics Inc.
Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.
Technical Analysis
Pharmarise Holdings Corp.
―
COSMOS Pharmaceutical Corporation
―
Tsubota Laboratory Incorporated
―
Shinnihonseiyaku Co., Ltd.
―
Heartseed, Inc.
―